Human leukocyte antigen class II complex (HLA-II) presenting melanoma-associated peptides (HLA-II/MAP complex)

Human leukocyte antigen (HLA) class II molecules presenting melanoma-derived peptides are critical targets in the development of personalized cancer immunotherapies. While HLA class II molecules (such as HLA-DR, HLA-DQ, and HLA-DP) are typically found on professional antigen-presenting cells, they are often aberrantly expressed on melanoma cells, particularly in response to interferon-gamma (Johnson et al., 2016). These molecules present specific peptides derived from melanoma-associated antigens (e.g., MAGE-A3, NY-ESO-1, Tyrosinase) to CD4+ T cells (Yao et al., 2016). Recognition of these complexes by the T-cell receptor (TCR) triggers CD4+ T-cell activation, which can provide essential help for CD8+ T-cell responses or exert direct cytotoxic effects on the tumor (Pollack et al., 2017). Therapeutic interventions, such as TCR-engineered T-cell therapies and peptide vaccines, aim to exploit these complexes to induce a potent and specific anti-tumor immune response. However, clinical success depends on the precise matching of the patient's HLA genotype and the expression of the specific melanoma antigen within the tumor (Zhao et al., 2006). Challenges include the high polymorphism of HLA alleles and the potential for tumor escape through the downregulation of MHC molecules or antigen loss. Overall, these pMHC-II complexes represent a high-specificity approach to leveraging the CD4+ T-cell compartment in melanoma treatment.

Other names

MHC class II-melanoma peptide complexHLA-DR-melanoma antigen complexpMHCII melanoma complexMelanoma-associated antigen-HLA-II complex

The primary mechanism involves the high-affinity binding of engineered or endogenous T-cell receptors (TCRs) to the peptide-HLA class II complex on the surface of melanoma cells. This binding event triggers the activation of CD4+ T cells, resulting in the secretion of pro-inflammatory cytokines such as interferon-gamma and tumor necrosis factor-alpha, which enhance the overall anti-tumor immune response and can lead to direct tumor cell apoptosis (Yao et al., 2016; Pollack et al., 2017).